Read + Share
Vukusic S, Hubben F, Gavoille A, Malek Y, et al. Beyond the switch to the biosimilar of natalizumab: What is the impact of
changing the JCV test? Mult Scler 2025;31:877-881.
PMID: 40515642
|
 |
|
Vukusic S, Hubben F, Gavoille A, Malek Y, et al. Beyond the switch to the biosimilar of natalizumab: What is the impact of
changing the JCV test? Mult Scler 2025;31:877-881.
PMID: 40515642
|
|
|
|